Post-marketing Observational Study to Evaluate the Incremental Impact of AbbVie's Patient Support Program on Patient Reported Outcomes and Health Resource Utilization in Inflammatory Arthritis, Psoriasis and Inflammatory Bowel Diseases in Hungary (VALUE)

The health assessment questionnaire Short Form 36 Version 2.0 (SF-36 V2 ) determines participants' overall quality of life by assessing 1) limitations in physical functioning due to health problems; 2) limitations in usual role because of physical health problems; 3) bodily pain; 4) general health perceptions; 5) vitality; 6) limitations in social functioning because of physical or emotional problems; 7) limitations in usual role due to emotional problems; and 8) general mental health. Items 1-4 primarily contribute to the physical component summary score (PCS) of the SF-36. Items 5-8 primarily contribute to the mental component summary score (MCS) of the SF-36. Scores on each item are summed and averaged (range = 0 worst-100 best). Positive numbers indicate improvement from baseline.

Time frame: Baseline (Month 0) and 12 months

Population: All participants in the Full Analysis Set with evaluable data

To define possible correlations between disease activity scores and disease specific quality of life scores, correlation analyses were performed. Correlation between patient socio-demographics, patient type and indication was not completed because these were uninterpretable per protocol. ASQoL= Ankylosing Spondylitis Quality of Life questionnaire ASDAS(ESR) = Ankylosing Spondylitis Disease Activity Score; laboratory parameter is a measurement of erythrocyte sedimentation rate (mm/hour; ESR) DAS28(ESR)= Disease Activity Score 28; laboratory parameter is a measurement of erythrocyte sedimentation rate (mm/hour; ESR) SIBDQ= Short Quality of Life in Inflammatory Bowel Disease Questionnaire CDAI= Clinical Disease Activity Index DLQI= Dermatology Life Quality Index PASI= Psoriasis Area and Severity Index pMayo= Partial Mayo score (Mayo score without endoscopy)

Time frame: Baseline (Month 0) and 12 months

Population: All participants in the Full Analysis Set with evaluable data

The effectiveness of the AbbVie Care 2.0 patient care support program (PSP) on participant outcomes was to be analyzed by applying mixed linear models on outcomes including PSP utilization (continuous vs terminated) as fixed variables. Baseline participant outcome values were also to be included in the model.

Time frame: From Baseline (Month 0) to 12 months

Population: Assessment of the effectiveness of the length of PSP exposure on participant outcomes was not possible because of the low number of participants in the non-PSP group.

The Ankylosing Spondylitis Disease Activity Score (ASDAS) tool is a self-administered questionnaire/objective laboratory evaluation. The questionnaire assesses disease activity, back pain, and peripheral pain/swelling on a numeric rating scale (from 0 (normal) to 10 (very severe)) and duration of morning stiffness on a numeric rating scale (from 0 to 10, with 0 being none and 10 representing a duration of ≥2 hours). The laboratory parameter is a measurement of erythrocyte sedimentation rate (mm/hour; ESR). Data from five variables (disease activity, back pain, duration of morning stiffness, peripheral pain/swelling, and ESR) are combined to yield a score (0 to no defined upper limit). Negative values indicate improvement from baseline.

Time frame: Baseline (Month 0) and 12 months

Population: All participants in the Full Analysis Set with either ankylosing spondylitis or psoriatic arthritis with axial symptoms and evaluable data

The Ankylosing Spondylitis Quality of Life (ASQoL) questionnaire is a disease-specific instrument designed to measure health related quality of life (HRQOL) in participants with AS. Participants answer yes/no to 18 items assessing the current impact of AS on their quality of life status. The total score ranges from 0 to 18, with lower scores representing better AS-specific quality of life. Negative numbers indicate improvement from baseline.

Time frame: Baseline (Month 0) and 12 months

Population: All participants in the Full Analysis Set with either ankylosing spondylitis and or psoriatic arthritis with axial symptoms and evaluable data

The Crohn's Disease Activity Index (CDAI) is a research tool used to quantify the symptoms of patients with Crohn's disease. Participants were asked to record the frequency of stools, abdominal pain and general well-being on a daily basis. In addition to the diary data, the investigator assessed the following for the calculation of CDAI: presence of complications (arthritis/arthralgia, iritis/uveitis, erythema nodosum/pyoderma gangrenosum/aphthous stomatitis, anal fissure/fistula/abscess, other fistula, and fever), the use of antidiarrheal medicines, presence of an abdominal mass, hematocrit, and body weight. The CDAI is the sum of the products of each item multiplied by a weighting factor and generally ranges from 0 up to 600, where remission of Crohn's disease is defined as CDAI \< 150, and severe disease is defined as CDAI \> 450. Negative values indicate improvement from baseline.

Time frame: Baseline (Month 0) and 12 months

Population: All participants in the Full Analysis Set with Crohn's disease and evaluable data

The Dermatology Life Quality Index (DLQI) is a self-reported questionnaire for capturing psychosocial effects of chronic skin disease on different areas of life within the previous seven days. The ten questions cover six areas: symptoms/feelings, daily activities, leisure, work/school, personal relationship, effects of treatment on daily life. Total DLQI scores range from 0 to 30, with 0 corresponding to the best quality of life and 30 to the worst. Negative numbers indicate improvement from baseline.

Time frame: Baseline (Month 0) and 12 months

Population: All participants in the Full Analysis Set with either psoriasis or psoriatic arthritis and evaluable data

The Disease Activity Score 28 (DAS28) is a validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, the erythrocyte sedimentation rate (ESR), and the patient's assessment of global disease activity (on a visual analog scale \[VAS\] from 0 to 10 cm) are included in the DAS28 score. Scores on the DAS28 range from 0 to 10; higher scores indicate more disease activity. A DAS28 score \>5.1 indicates high disease activity, a DAS28 score \<3.2 indicates low disease activity, and a DAS28 score \<2.6 indicates clinical remission. Negative values indicate improvement from baseline.

Time frame: Baseline (Month 0) and 12 months

Population: All participants in the Full Analysis Set with either psoriatic arthritis with peripheral symptoms or rheumatoid arthritis and evaluable data

The EQ-5D-5L measures quality of life in five dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) each of which are rated on five levels of severity (1: no problems, 2: slight problems, 3: moderate problems, 4: severe problems, 5: extreme problems), and a separate visual analog scale (VAS). Responses to the five dimension scores were combined and converted into a single preference-weighted health utility index score. The range for the EQ-5D-5L index score is 0 to 1 with '0' defined as a health state equivalent to being dead and '1' is full health. The higher the score the better the health status. Positive numbers indicate improvement from baseline.

Time frame: Baseline (Month 0) and 12 months

Population: All participants in the Full Analysis Set with evaluable data

The EQ-5D-5L measures quality of life in five dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) each of which are rated on five levels of severity (1: no problems, 2: slight problems, 3: moderate problems, 4: severe problems, 5: extreme problems), and a separate visual analog scale (VAS). Participants rated their health on a vertical visual analogue scale, where the endpoints were labelled 100, The best health you can imagineand 0, The worst health you can imagine. Positive numbers indicate improvement from baseline.

Time frame: Baseline (Month 0) and 12 months

Population: All participants in the Full Analysis Set with evaluable data

The WPAI-SHP is a questionnaire used to assess the effect of the participant's health problems on their ability to work and perform regular activities. Presenteeism indicates the percentage of impairment while working due to health problems. Absenteeism indicates the percentage of work time missed due to health problems. Total activity impairment (TAI) indicates the percentage of general (non-work) activity impairment due to health problems. Total work productivity impairment (TWPI) indicates the percentage of overall work impairment due to health problems. Results of WPAI are expressed as a percentage of impairment from 0 to 100, with higher percentages indicating greater impairment and less productivity. Negative numbers indicate improvement from baseline.

Time frame: Baseline (Month 0) and 12 months

Population: All participants in the Full Analysis Set with evaluable data; participants who were employed with available data at baseline and 12 months are included

The Partial Mayo score (Mayo score without endoscopy) ranges from 0 (normal or inactive disease) to 9 (severe disease) and is calculated as the sum of 3 subscores (stool frequency, rectal bleeding and physician's global assessment \[PGA\]), each of which ranges from 0 (normal) to 3 (severe disease). Negative values indicate improvement from baseline.

Time frame: Baseline (Month 0) and 12 months

Population: All participants in the Full Analysis Set with ulcerative colitis and evaluable data

The Psoriasis Area and Severity Index (PASI) is a combination of the intensity of psoriasis, assessed by the erythema (reddening), induration (plaque thickness) and desquamation (scaling) on a scale from no symptoms (0), slight (1), moderate (2), marked (3) or very marked (4), together with the percentage of the area affected, rated on a scale from 0 to 6. PASI scoring is performed at four body areas, the head, arms, trunk, and legs. The total PASI score ranges from 0 to 72. The higher the total score, the more severe the disease. Negative values indicate improvement from baseline.

Time frame: Baseline (Month 0) and 12 months

Population: All participants in the Full Analysis Set with psoriasis and evaluable data

The health assessment questionnaire Short Form 36 Version 2.0 (SF-36 V2 ) determines participants' overall quality of life by assessing 1) limitations in physical functioning due to health problems; 2) limitations in usual role because of physical health problems; 3) bodily pain; 4) general health perceptions; 5) vitality; 6) limitations in social functioning because of physical or emotional problems; 7) limitations in usual role due to emotional problems; and 8) general mental health. Items 1-4 primarily contribute to the physical component summary score (PCS) of the SF-36. Items 5-8 primarily contribute to the mental component summary score (MCS) of the SF-36. Scores on each item are summed and averaged (range = 0 worst-100 best). Positive numbers indicate improvement from baseline.

Time frame: Baseline (Month 0) and 12 months

Population: All participants in the Full Analysis Set with evaluable data

The SIBDQ is a disease-specific health-related quality of life (HRQOL) questionnaire, able to detect and define meaningful clinical changes in inflammatory bowel disease (IBD) participants by measuring physical, social and emotional status. The SIBDQ consists of 10 questions; each question is scored on a scale from 1 (poor QOL) to 7 (optimum QOL). A higher score indicates a better health-related quality of life. Total scores range from 10 (poor QoL) to 70 (good QoL). Positive numbers indicate improvement from baseline.

Time frame: Baseline (Month 0) and 12 months

Population: All participants in the Full Analysis Set with either Crohn's disease or ulcerative colitis and evaluable data

The Morisky Medication Adherence Scale-4 (MMAS-4 ) is a 4-item self-reported measure of medication-taking behavior. It measures intentional and non-intentional non-adherence. The MMAS-4 score is the sum of four questions and ranges from 0 to 4: The coding is 0, 1 (low adherence), 2, 3 (moderate adherence) and 4 (high adherence). Positive numbers indicate improvement from baseline.

Time frame: Baseline (Month 0) and 12 months

Population: All participants in the Full Analysis Set with evaluable data

The Satisfaction with Information about Medicines Scale (SIMS) assesses whether an individual has received enough information about a range of topics relating to prescribed medication. Participants are asked to rate the amount of information they have received using the following response scale: too much, about right, too little, none received, none needed. Total satisfaction rating is obtained by summing the scores for each item. If the participant is satisfied that he/she has received a particular aspect of medication information (with a rating of about right or none needed), this is given a score of 1. If the participant is dissatisfied with the amount of information received (with a rating of too much, too little, or none received), this is scored 0. Total scores range from 0 to 17 with high scores indicating a high degree of overall satisfaction with the amount of medication information received. Positive numbers indicate improvement from baseline.

Time frame: Baseline (Month 0) and 12 months

Population: All participants in the Full Analysis Set with evaluable data

The 14-item Treatment Satisfaction Questionnaire for Medication (TSQM) Version 1.4 is an instrument to show that adherence is expected to be related with participants' satisfaction with therapy and that such satisfaction can be a function of not only the effect of the treatment, but also the services offered. TSQM responses are used to derive scores for scales measuring effectiveness, side effects, convenience, and global satisfaction (based on participant evaluation over the last 2 to 3 weeks, or since last medication use). Scores for each of the 4 scales range from 0 to 100 with higher scores indicating a better state or outcome (e.g., greater perceived effectiveness or satisfaction). Positive numbers indicate improvement from baseline.

Time frame: Baseline (Month 0) and 12 months

Population: All participants in the Full Analysis Set with evaluable data

The number of hospital inpatient days over the 3 months preceding the first adalimumab administration was documented and multiplied by 4 to obtain an estimate of 12-month data. The 12-month total post-treatment hospital inpatient days was obtained by adding the values obtained at months 3, 6, 9, and 12. The number of sick leave days (in employed participants) over the 3 months preceding the first adalimumab administration was documented and multiplied by 4 to obtain an estimate of 12-month data. The 12-month total post-treatment sick leave days was obtained by adding the values obtained at months 3, 6, 9, and 12. Negative numbers indicate improvement from the prior 12 months.

Time frame: 12 months prior to treatment start (Month 0 [baseline]) and 12 months after treatment start (total 24 months)

Population: All participants in the Full Analysis Set with evaluable data; participants who were employed with available data at baseline and 12 months are included

The number of hospitalizations over the 3 months preceding the first adalimumab administration was documented and multiplied by 4 to obtain an estimate of 12-month data. The 12-month total hospitalizations were obtained by adding the values obtained at months 3, 6, 9, and 12. The number of sick leaves (in employed participants) over the 3 months preceding the first adalimumab administration was documented and multiplied by 4 to obtain an estimate of 12-month data. The 12-month total sick leaves were obtained by adding the values obtained at months 3, 6, 9, and 12. Negative numbers indicate improvement from the prior 12 months.

Time frame: 12 months prior to treatment start (Month 0 [baseline]) and 12 months after treatment start (total 24 months)

Population: All participants in the Full Analysis Set with evaluable data; participants who were employed with available data at baseline and 12 months are included

The number of outpatient visits to general practitioners, immune-mediated inflammatory disease specialists, ophthalmologists, gastroenterologists, dermatologists, rheumatologists, physiatrists, physiotherapists, and nurses over the 3 months preceding the first adalimumab administration was documented and multiplied by 4 to obtain an estimate of 12-month data. The 12-month total outpatient visits were obtained by adding the values obtained at months 3, 6, 9, and 12. Negative numbers indicate improvement from the prior 12 months.

Time frame: 12 months prior to treatment start (Month 0 [baseline]) and 12 months after treatment start (total 24 months)

Population: All participants in the Full Analysis Set with evaluable data. Data were not collected for visits to physiatrists and physiotherapists in the Psoriasis Arm/Group, and for visits to physiatrists in the Rheumatoid Arthritis Arm/Group.

All participants enrolled in the study were enrolled in the AbbVie Care 2.0 patient support (PSP) program. Participants rated the PSP program as either Very good, good, less satisfying or I do not use the services at the last study visit.

Time frame: 12 months

Population: All participants in the Full Analysis Set with evaluable data